Correspondence
In Brief Dysregulation of UPR signaling in neurons is a key mediator of neurodegeneration. Smith et al. show that UPR dysregulation in astrocytes impairs their ability to support synapses; modulating astrocytic UPR signaling prevents neuronal loss and increases survival in prion-diseased mice.
INTRODUCTION
The buildup of misfolded proteins, characteristic of many neurodegenerative diseases, is a cellular stress that results in activation of the unfolded protein response (UPR), a signaling cascade that aims to restore protein homeostasis (Ron and Walter, 2007) . One branch of the UPR, mediated by phosphorylation of protein kinase R-like ER kinase (PERK), leads to the transient shutdown of protein synthesis through phosphorylation of the a subunit of eukaryotic initiation factor 2 (eIF2a) ( Figure 1A) . In several mouse models of neurodegeneration, chronic PERK-eIF2a-P signaling results in the sustained reduction in global protein synthesis rates, leading to synaptic failure and neuronal loss Radford et al., 2015) . Restoration of translation rates in neurons through genetic or pharmacological modulation of PERK-eIF2a-P signaling restores memory and synapse function (Costa-Mattioli et al., 2007; Ma et al., 2013; Sidrauski et al., 2013) and is profoundly neuroprotective in these models (Celardo et al., 2016; Grande et al., 2018; Halliday et al., 2015 Halliday et al., , 2017 Kim et al., 2014; Mercado et al., 2018; Moreno et al., , 2013 Radford et al., 2015) . The pathway has become an area of intense interest for the treatment of human neurodegenerative disorders, where increased levels of PERK-P and eIF2a-P occur in association with misfolded protein accumulation in Alzheimer's and Parkinson's diseases and related disorders (Hoozemans et al., 2005 (Hoozemans et al., , 2007 (Hoozemans et al., , 2009 Smith and Mallucci, 2016; Stutzbach et al., 2013) .
Although the neuronal, cell-autonomous effects of dysregulated PERK signaling in neurodegeneration are relatively well understood, the role of astrocytic UPR activation in disease is unknown. Astrocytes are key modulators of synaptic structure and function (Allen et al., 2012; Christopherson et al., 2005; Chung et al., 2013; Kucukdereli et al., 2011) , and their activation to a ''reactive'' state is a common feature of neurodegenerative disorders. Recent observations describe ''neurotoxic'' and ''neuroprotective'' reactivity states (Liddelow et al., 2017; Zamanian et al., 2012) . However, the mechanisms driving astrocyte reactivity during disease and how this impacts on function and pathogenesis remain unclear. In this study, we show that chronic PERK-eIF2a signaling in astrocytes drives a distinct pathogenic reactivity state both in vitro and in vivo. This state, which we term ''UPR'' reactive, is characterized by an astrocytic secretome devoid of synaptogenic properties. It is reversed by PERK inhibition, which restores synaptogenesis in vitro. Critically, in vivo, modulation of astrocytic PERK-eIF2a signaling in mice with prion disease is profoundly neuroprotective, abrogating clinical signs and prolonging survival, despite ongoing neuronal PERK activation. The pathogenic role of PERK over-activation therefore has a significant, non-cell-autonomous component, generating a distinct reactivity state in astrocytes principally through loss of synaptotrophic function; this provides multiple new targets for restoring synapses and neuroprotection in neurodegenerative diseases with PERK pathway dysregulation.
RESULTS

Chronic PERK Branch Activation Drives a Distinct UPR-Reactivity Profile in Primary Cultured Astrocytes
We first confirmed PERK-eIF2a signaling ( Figure 1A ) in astrocytes in vitro and characterized its temporal profile. Primary astrocytes, cultured from wild-type mice, were treated with the ER stressors thapsigargin (Tg) or tunicamycin (Tm) for 2, 6, or 24 h. PERK activation occurred following 2 h of Tg treatment, with significantly increased levels of phosphorylated PERK (PERK-P) and phosphorylated eIF2a (eIF2a-P) at this time point (Figure 1B) , consistent with previous reports (Guthrie et al., 2016; Sprenkle et al., 2019) . This corresponded with an 88% reduction in global protein synthesis rates at 2 h as a result of rising eIF2a-P levels ( Figure 1C ). Elevated levels of the downstream markers of eIF2a-P signaling, ATF4 and GADD34, were found after 6 and 24 h of Tg treatment, respectively ( Figure 1B) . Tm, which activates the UPR through a different mechanism to Tg, drove a similar temporal pattern of PERK-eIF2a signaling (Figures S1B-S1E). Thus, primary cultured astrocytes exhibit a typical PERK-pathway response to ER stressors.
Next, we asked whether PERK signaling affects astrocyte reactivity in vitro. We assessed the expression levels of a selection of astrocyte reactivity markers, including ''pan,'' ''A1,'' and ''A2'' markers (Liddelow et al., 2017; Zamanian et al., 2012) , following Tg treatment. The A1 reactivity state, described in response to a peripheral inflammatory stimulus, is proposed to be neurotoxic in vitro, whereas the A2 reactivity state, described in response to ischemia, is proposed to be neuroprotective (Liddelow et al., 2017; Zamanian et al., 2012) . By 24 h of Tg treatment, the pan-reactive markers Cxcl10, Lcn2, and Vim and the A1 marker C3 were significantly elevated, with 107-fold, 17-fold, 1.8-fold, and 8-fold increases in mRNA levels, respectively ( Figure 1E ). In contrast, Ggta1 and Serping1 (also A1 markers) were significantly reduced, as were Cd109, Emp1 (A2 markers), and the pan-reactive marker, Serpina3n, with 47%, 81%, 90%, 60%, and 52% reductions in transcript levels, respectively ( Figure 1E ). Tm treatment induced a similar reactivity profile at 24 h ( Figure S1H ). Only Emp1 and S100a10 transcript levels differed in the profiles generated by the two ER stressors. Critically, the small molecule GSK2606414, a potent inhibitor of PERK kinase signaling , prevented the Tg-induced rise in eIF2a-P, ATF4, and GADD34 (Figures 1G and 1H) and, in parallel, significantly reduced the changes to the reactivity profile when co-administered with Tg ( Figure 1I ) or Tm ( Figure S1H ), blunting the increase in Cxcl10, Lcn2, and Vim. Trazodone, a drug that acts downstream of eIF2a-P to reverse PERK-eIF2a-P signaling (Halliday et al., 2017) , also reduced the elevated expression of Cxcl10, Lcn2, and Vim, as well as C3, on Tg treatment ( Figure S1I ). To exclude any off-target effects of GSK2606414 (Mahameed et al., 2019; Rojas-Rivera et al., 2017) , we genetically modulated PERK-eIF2a signaling using small interfering RNA (siRNA) targeting PERK expression. A 73% knockdown of PERK expression significantly reduced the levels of eIF2a-P on Tg treatment and, crucially, lowered C3, Cxcl10, Lcn2, and Vim, with 61%, 51%, 82%, and 60% reductions in transcript levels, respectively ( Figure S2 ). Thus, PERK signaling is the primary mediator of a distinct astrocytic reactivity profile in vitro ( Figure 1F ). We term these astrocytes UPR reactive.
UPR-Reactive Astrocytes Fail to Support Synapses
In Vitro due to an Altered Secretome We next tested for functional effects of the PERK-mediated changes to the astrocyte reactivity state. Astrocytes and astrocyte-conditioned media (ACM) have marked trophic effects on synaptogenesis in primary neuronal cultures (Allen et al., 2012; Christopherson et al., 2005; Ullian et al., 2001) . We therefore assessed the synaptogenic properties of conditioned media from UPR-reactive astrocytes (Figure 2A ). ACM from vehicle-treated astrocytes significantly increased the synaptic density of primary hippocampal neurons by 1.65-fold ( Figures 2B and 2C ), consistent with previous reports (Allen et al., 2012) . In contrast, ACM from Tg-treated astrocytes had no effect on synapse number (Figures 2B and 2C) . PERK inhibition restored the synaptogenic properties of the ACM, with ACM derived from GSK2606414treated Tg-stressed astrocytes significantly increasing synapse number by 1.47-fold ( Figures 2B and 2C ). Thus, PERK activation reduces the synaptogenic function of astrocytes as a result of the altered UPR-reactivity state.
To better understand the mechanisms underlying the loss of astrocytic synaptotrophism upon chronic PERK activation, we compared the secretome of vehicle and Tg-treated astrocytes using unbiased liquid chromatography/mass spectrometry (LC/ MS) analysis. Conditioned media from vehicle-treated astrocytes contained an array of proteins essential for synapse maintenance; constituents of the extracellular matrix, such as collagen, fibronectin, and glypican-4, a key synaptogenic factor (Allen et al., 2012) , were particularly abundant ( Figure 3A ; see Table S1 for full list). The abundance of proteins in the secretome was markedly altered by Tg treatment, with 34 out of the 127 proteins detected showing at least a 1.3-fold reduction in spectral counts compared to the secretome of vehicle-treated astrocytes (Figures 3A and 3B) . KEGG (Kyoto Encyclopedia of Gene and Genomes) and Gene Ontology analysis revealed that extracellular matrix and cell adhesion pathways were most significantly affected by Tg treatment (p = 6.9 3 10 À7 and 4.6 3 10 À5 , respectively; Figure 3C ). Downregulation of these pathways generally, and of the levels of collagen, fibronectin, and glypican-4, specifically, likely explains the loss of synaptotrophic support from UPR-reactive astrocytes. Interestingly, 41/127 (32%) proteins showed a 1.3-fold or greater increase in spectral counts on Tg treatment ( Figure 3B ; Table S1 ). These proteins were largely chaperones involved in protein folding and processing in the ER, consistent with UPR activation, and included BiP and the neurotrophic factor, MANF (Figures 3B and S3; Table S1 ). 52/127 (41%) proteins showed no change in abundance on Tg treatment ( Figure 3B ; Table S1 ). Thus, it is likely that changes to the secretome induced by Tg treatment do not solely reflect the reduction in global protein synthesis rates that accompany PERK activation ( Figure 1C ) but likely reflect changes in the astrocytic translatome under these conditions. PERK inhibition largely reversed the changes to protein abundance ( Figure 3A ; Table S1 ). The UPR-reactivity state resulting from chronic PERK branch activation therefore alters the secretome of primary astrocytes, to the detriment of synaptic trophism.
Astrocytic PERK-eIF2a Signaling Drives a UPR-Reactivity State In Vivo that Is Reversed by Genetic Modulation of the Pathway Given the effect of PERK signaling on astrocyte reactivity in vitro ( Figures 1E and S1H ), we next examined whether this also occurs in vivo. We used the tg37 +/À mouse model of prion disease, which has been extensively characterized with respect to PERK-eIF2a signaling and its modulation, particularly in neurons (Halliday et al., , 2017 Moreno et al., , 2013 . Tg37 +/À mice express around $3-fold wild-type levels of prion protein (PrP) and succumb to RML (Rocky Mountain Laboratory) prion infection 12 weeks post-inoculation (w.p.i.) (Mallucci et al., 2002 (Mallucci et al., , 2003 (Mallucci et al., , 2007 . Rising levels of misfolded PrP result in high PERK-P and eIF2a-P and reduced translation rates in the hippocampus from 9 w.p.i., followed by the onset of neuronal loss at 10 w.p.i., with the emergence of overt clinical signs and widespread neurodegeneration by 12 w.p.i. . The mice show prominent astrocytosis from 8 w.p.i., with increased GFAP staining over the course of the disease (Figure S4A) , consistent with previous reports (Mallucci et al., 2002 (Mallucci et al., , 2003 . PERK-P staining was detected in astrocytes and neurons in the CA1 region of prion-infected mice at 10 w.p.i. ( Figure S4B ).
We examined hippocampal homogenates of prion-diseased mice at 10 w.p.i., when PERK signaling is known to be activated and reactive astrocytosis is established ( Figure S4A ). We tested for expression of UPR-reactivity markers defined in vitro (Figures 1E and 1F) and found a pattern of mRNA transcript expression very similar to that seen in Tg-and Tmstressed astrocytes (Figures 1E, 1F , and S1H). Thus, mRNA levels of C3, Cxcl10, Lcn2, and Vim rose significantly from 9 w.p.i. (Figures 4A and S5A ), in parallel with increased PERK-eIF2a signaling ( Figure S5C ), and remained elevated through to the terminal stages of the disease (Figures 4A and S5A ). mRNA levels of Lcn2, a pan-reactive marker, increased more than 250-fold in terminal prion-diseased mice compared to control tg37 +/À mice ( Figure 4A ). Transcript levels of Sox9, an astrocyte-specific nuclear marker, were unchanged through the disease course ( Figure S5A ), consistent with an altered reactivity state rather than merely reflecting an increase in astrocyte number. RNA scope ( Figure 4B ) and immunohistochemistry ( Figures  4C and 4D ) confirmed the astrocytic origins of C3 and Lcn2 transcript and protein, respectively, in prion-diseased mice at 10 w.p.i. The rise in these proteins occurred at 9 w.p.i., in line with increased PERK-eIF2a signaling ( Figures S5B-S5D) .
In order to modulate PERK-eIF2a signaling specifically in astrocytes, we generated lentiviral vectors that overexpress an active fragment of GADD34 (DhuGADD34), the specific inducible phosphatase of eIF2a-P, under the astrocytic promoter GFAP ( Figure S6A ). LV-GFAP-DhuGADD34-transduced primary astrocytes ( Figure S6B ) resulted in reduced eIF2a-P levels and increased protein synthesis rates on Tg treatment ( Figures S6C  and S6D ), confirming both functionality of the virus and efficacy of GADD34 activity in cultured astrocytes. In vivo, mice were injected with LV-GFAP-DhuGADD34 at 5 w.p.i. to allow for viral expression as disease progressed. Astrocytic expression of the viral construct was confirmed through detection of lentivirally mediated expression of GFP (linked to DhuGADD34) in hippocampal sections ( Figure S6E ). Virally expressed DhuGADD34 caused reduced eIF2a-P levels in prion-infected mice at 10 w.p.i. (Figures S6F and S6G) . Critically, LV-GFAP-DhuGADD34 treatment of prion-infected mice reduced the astrocyte reactivity profile (Figures 5A, S6H, and S6I) , consistent with the effects of PERK inhibitor treatment in vitro ( Figure 1G ). Levels of C3, Cxcl10, Lcn2, and Vim were reduced by 53%, 63%, 46%, and 35%, respectively, at 10 w.p.i. following LV-GFAP-DhuGADD34 injection ( Figures 5A and S6I) . The reduction in C3 and Lcn2 transcript levels in astrocytes of GADD34-treated mice was confirmed by RNA scope (Figure 5B ). C3 and LCN2 protein levels were also significantly reduced in LV-GFAP-DhuGADD34treated mice, consistent with reduced astrocyte activation ( Figures 5C and 5D ).
Targeting PERK-eIF2a Signaling in Astrocytes In Vivo Is Profoundly Neuroprotective In vitro, inhibiting PERK signaling restored the synaptogenic properties of Tg-stressed astrocytes ( Figures 2B and 2C) . We next asked what were the functional sequelae of modulating PERK signaling in astrocytes in vivo, in the context of over-activation of the pathway during prion neurodegeneration. We first observed that lentivirally mediated astrocyte-specific GADD34 expression in prion-diseased mice resulted in a significant and sustained improvement in burrowing behavior ( Figure 6A) , a motivational task sensitive to hippocampal (notably CA1) integrity that correlates with early synaptic dysfunction in prion disease (Deacon et al., 2001; Mallucci et al., 2007) . Control mice treated with an ''empty'' virus showed a steady decline in burrowing from 8 w.p.i. In parallel, astrocytic expression of GADD34 reduced spongiform degeneration ( Figure 6B , h versus f and g) and largely prevented neurodegeneration in the hippocampus ( Figure 6B , a-h). Astrocytic GADD34 expression resulted in marked neuroprotection: LV-GFAP-DhuGADD34treated mice showed 67% more pyramidal neurons in the CA1-CA3 region at 12 w.p.i. than mice treated with LV-GFAPempty or no virus (p = 0.0002; Figures 6B, see h compared to f and g, and 6C). Further, lowering astrocytic PERK signaling through GADD34 overexpression not only reduced the activation state ( Figures 5A and S6I ) but also significantly decreased astrocyte density (Figures 6B, compare l with j and k, and 6D), with a 35% reduction in astrocyte numbers and markedly less activated morphology in GADD34-treated animals ( Figures 5C and  5D , e and f). Finally, lentivirally mediated modulation of astrocytic PERK signaling significantly increased survival in prion-diseased mice to 87 ± 2 days, compared to 82 ± 2 days in mice treated with empty virus (p = 0.0009; Figure 6E ). Although this increase may appear modest, this extension of lifespan is comparable to survival data where PERK signaling is similarly modulated in neurons, through lentiviral expression of DhuGADD34 under the neuron-specific CAMKII promoter, and is the result of focal modulation only ( Figure S6J ; . As with neuronally targeted PERK modulation, levels of PrP and its misfolded disease-associated isoform, PrP Sc , were unaffected by the interventions ( Figure S6K ). These data strongly implicate the role of astrocytic PERK signaling in neuronal demise during disease, through the loss of critical synaptotrophic support.
DISCUSSION
The processes leading to neurodegeneration involve several cell types other than neurons. The role of microglia in these disorders has been extensively studied, but although astrocyte activation and reactivity are well documented, the mechanisms underlying C3 (magenta) and Lcn2 (white) to GFAP + astrocytes (green) in the hippocampus of prion-diseased mice at 10 w.p.i. (C and D) Immunostaining of C3 (C) and LCN2 (D) in the hippocampus of prion-diseased mice at 10 w.p.i. Scale bars, 100 mm. (E) Prion-diseased mice showed a significant increase in the number of C3 + /GFAP + and LCN2 + /GFAP + astrocytes. Bar graphs show mean ± SEM; ***p < 0.001; Student's t test. n = 3 mice. the astrocytic response to neurodegeneration are still largely unresolved. These cells were the focus of our study.
The pathogenic role of dysregulated PERK-eIF2a-P signaling in neurons has been well characterized across the spectrum of neurodegenerative disorders (Grande et al., 2018; Halliday et al., 2015 Halliday et al., , 2017 Hoozemans et al., 2005 Hoozemans et al., , 2007 Kim et al., 2014; Mercado et al., 2018; Moreno et al., , 2013 Radford et al., 2015; Stutzbach et al., 2013) . PERK-P has been detected in astrocytes from human tauopathy diseases (Nijholt et al., 2012) , but the pathogenic effect of astrocytic PERK signaling, if any, in these disorders is unknown. Interestingly, the integrated stress response (ISR), mediated by eIF2a-P signaling, is dysregulated in astrocytes and oligodendrocytes in a group of neurodegenerative disorders known as vanishing white matter disease (VWMD). In these diseases, mutations in eIF2B, the key interactor of eIF2a-P, lead to demyelination and white matter loss (Schiffmann et al., 1994; van der Knaap et al., 1997) through altered eIF2a-P signaling in these cells. Here, we show that UPR activation in astrocytes, specifically PERK-eIF2a-P signaling, generates a distinct reactivity state both in vitro and in vivo, associated with loss of astrocytic synaptic trophism and neuroprotective functions. Inhibition of astrocytic PERK signaling reverses this activation state and restores synaptogenic properties to cultured astrocytes (Figures 1I, 2B, and  2C) . In vivo, it has the dramatic effect of affording extensive, profound neuroprotection with prevention of behavioral deficits and increased survival in prion-diseased mice (Figures 6A-6E ). The extended lifespan ( Figure 6E ) seen with focal hippocampal modulation of astrocytic PERK signaling is consistent with observed protective effects of lentiviral modulation of GADD34 in neurons and other neuroprotective genetic modifications in priondiseased mice Peretti et al., 2015) . This may result from hippocampal neuroprotection modifying behavior in treated mice in a way that allows a modest but significant and consistent increase in survival. Alternatively, it may reflect an extended time course of prion spread when the hippocampus is protected. We found a consistent ''UPR-reactive'' profile, generated in response to two different ER stressors in vitro, Tg and Tm ( Figures 1E and S1H) , and to the in vivo stress of disease-associated protein misfolding ( Figures 4A and S5) , specifically prion protein PrP Sc here. In each case, the profile is reversed by direct inhibition of PERK-P by GSK2606414 ( Figures  1H and S1H) or downstream of PERK, by inhibition of eIF2a-P signaling using trazodone ( Figure S1I ) or via lentivirally mediated GADD34 expression in vivo (Figures 5A and S6I) . The UPR-reactive profile shares a number of markers with previously described astrocyte reactivity states. A1 reactivity, which is dependent on microglial activation, in particular, has been suggested as representing a ''neurotoxic'' phenotype of astrocyte activation and has been attributed to contributing to pathogen-esis in a number of human neurodegenerative disorders. In fact, although A1 astrocytes are neurotoxic in vitro, the in vivo evidence for the A1 state in disease is confined to the presence of elevated C3 expression in post mortem samples from a variety of neurodegenerative diseases (Liddelow et al., 2017) . C3 elevation forms part of the UPR-reactivity profile, probably because this is a common feature of pathological astrocyte activation. However, the role, if any, of C3 in mediating pathogenesis is unclear, and our data support loss of synaptotrophic function of astrocytes over any direct toxic effect as the central pathological process here. Indeed, recent work identified a very similar profile in prion-diseased wild-type mice to the UPR-reactive state we describe, which the authors termed C3 + /PrP Sc -reactive (Hartmann et al., 2019) . Interestingly, the C3 + /PrP Sc -reactivity profile was largely unaffected by eliminating microglia-induced astrocyte activation, through genetic knockout of tumor necrosis factor alpha (TNF-a), interleukin-1a (IL-1a), and C1q, confirming its distinction from the A1 state. Indeed, this state may well respond instead to UPR inhibition, given its similarity to the UPR reactivity we describe in a different prion mouse model. Rather than A1, A2, and ''pan'' reactivity states, we suggest that there are likely to be multiple reactivity profiles for astrocytes in different diseases, driving pathogenesis through loss of neuronal tropism, with or without a degree of direct toxicity.
The importance of the PERK-mediated reactivity state in astrocytes is apparent through its mechanistic effects of altering the secretome, seen in primary astrocytes (Figure 3 ). UPR-activated astrocytes display a secretome largely devoid of synaptogenic properties. As a result, the astrocytic component of synapse development in cultured hippocampal neurons is absent ( Figure 2B ). Many extracellular matrix components, notably collagen, fibronectin, and filamin, known for their importance in synapse formation and maintenance (Ferrer-Ferrer and Dityatev, 2018; Hillen et al., 2018) , are reduced in UPR-reactive astrocytes ( Figure 3A) . PERK inhibition restores this property ( Figure 3A) . Critically, the secretome changes represent potential targets for synaptic rescue and neuroprotection for treatment of neurodegenerative diseases that would avoid systemic, widespread PERK pathway signaling modulation. Indeed, restoring synapse levels through synaptogenic pathways involving the cold-shock proteins RBM3 and RTN3 reverses cognitive deficits and prevents neurodegeneration in mouse models of Alzheimer's and prion disease (Bastide et al., 2017; Peretti et al., 2015) and is a powerful neuroprotective strategy. A more in-depth analysis of the astrocytic secretome-and proteome-may reveal further small molecules or peptides with synaptogenic properties that could be candidates for therapeutic intervention.
In conclusion, dysregulated PERK signaling in astrocytes generates a reactivity state that drives a marked non-cellautonomous mechanism of pathogenesis in prion neurodegeneration, likely to be relevant across the spectrum of these disorders in which PERK activation occurs. These include the tauopathies, including Alzheimer's disease and many other protein misfolding disorders. Targeting the astrocytic UPR, remarkably, is as protective as targeting the neuronal component. The data reveal new mechanisms by which astrocyte reactivity states contribute to neurodegeneration and provide novel potential synapse-specific targets for therapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giovanna Mallucci (gm522@cam.ac.uk) . All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Tg37 +/À mice, on a FVB background, were housed in a temperature-controlled room and were maintained on a 12:12 light dark cycle, with access to food and water ad libitum. Both males and females were used in this study. Mice were inoculated with 1% brain homogenate of Chandler/Rocky Mountain Laboratory (RML) prions or normal brain homogenate (NBH) at 3-4 weeks of age, as previously described . Prion-inoculated mice were monitored daily and were culled upon the appearance of confirmatory prion signs, which occur around 12 weeks post inoculation. Mice were randomly assigned to experimental groups. All animal work conformed to UK Home Office regulations and institutional and ARRIVE guidelines.
Primary astrocyte culture Primary astrocytes were isolated from the cortices of both male and female P1 C57BL6/N pups. Briefly, cortical tissue was extracted into Hibernate A media (GIBCO); meninges were removed and tissue was minced using a scalpel blade. The minced tissue was then incubated at 37 C for 5 minutes in fresh Hibernate A media supplemented with 1 mg/mL DNase (Sigma) and 0.25% Trypsin (GIBCO). The suspension was triturated then returned to 37 C for 5 minutes. Trituration was repeated and the suspension was incubated for a further 5 minutes. 10 mL of glial media (MEM, 10% horse serum, 0.6% D-glucose and 1% Penicillin/Streptomycin) was added and trituration was performed. The suspension was strained then centrifuged at 200 x g for 5 minutes. The cell pellet was re-suspended in glial media and seeded into T75 flasks (Corning). Cultures were maintained at 37 C, 5% CO 2 in glial media containing 1% horse serum. Upon reaching confluency, astrocytes were seeded into 6 well plates (Greiner) at a density of 100,000 cells per well.
Primary neuron culture
Primary neurons were isolated from the hippocampi of both male and female P1 C57BL6/N pups. Briefly, hippocampi were extracted into Hibernate A media (GIBCO) and incubated at 37 C with papain solution for 20 minutes. Papain solution was removed and trypsin 
